Bayer, Regeneron anti-blindness drug Eylea shown to work at higher dose, longer intervals
Frankfurt: Bayer said on Thursday that its anti-blindness treatment Eylea, jointly developed with Regeneron, was shown to work as well when given at a higher dose at a longer interval between injections.
Eylea, which is normally given at 2 milligrams every eight weeks, was shown in two late-stage trials to be as effective when given at 8 mg at longer intervals, without any additional safety issues, the German company said in a statement.
The results will help Bayer compete with Roche, while rival drug Vabysmo was launched this year. The Swiss drugmaker is seeking to win over patients with longer intervals between injections.
Read also: Bayer unveils drug for CKD associated with diabetes under brand name Kerendia
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd